Mirum Pharmaceuticals Announces Data From EMBARK Phase 2b Study for Biliary Atresia; Study Did Not Meet Primary Or Secondary Endpoints
Portfolio Pulse from Benzinga Newsdesk
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) reported that its Phase 2 EMBARK study for LIVMARLI as a treatment for biliary atresia failed to meet primary or secondary endpoints. The drug was well-tolerated with no new safety issues. The company expressed disappointment but gratitude towards participants for advancing the science of this rare liver disease.
December 18, 2023 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mirum Pharmaceuticals' EMBARK study for LIVMARLI did not meet primary or secondary endpoints, which could negatively impact investor sentiment and stock price in the short term.
Failure to meet study endpoints often leads to negative investor sentiment, as it casts doubt on the drug's potential for approval and future revenue. However, the absence of new safety concerns may mitigate some negative impact.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100